Pancreatic Cancer Clinical Trials in Pittsburgh

Showing 61-80 of 163 trials

Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms

NCT01640522

The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.

Hepatocellular CarcinomaPrimary Liver CancerBile Duct Cancer+4 more

University of Pittsburgh261 participantsStarted Jan 2008

Pittsburgh, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01064622

This randomized phase I/II trial studies gemcitabine hydrochloride and vismodegib to see how well they work compared with gemcitabine hydrochloride alone in treating patients with recurrent or metastatic pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vismodegib may slow the growth of tumor cells. It is not yet known whether giving gemcitabine hydrochloride together with vismodegib is more effective than gemcitabine hydrochloride alone in treating patients with pancreatic cancer.

Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage IV Pancreatic Cancer AJCC v6 and v7

National Cancer Institute (NCI)118 participantsStarted Sep 2009

Beverly Hills, California, United States • Duarte, California, United States • Los Angeles, California, United States +22 more locations

Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Milademetan in Advanced/Metastatic Solid Tumors

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Other Conditions in Pittsburgh